SG166117A1 - Methods and compositions for treatment of interferon-resistant tumors - Google Patents

Methods and compositions for treatment of interferon-resistant tumors

Info

Publication number
SG166117A1
SG166117A1 SG201007186-8A SG2010071868A SG166117A1 SG 166117 A1 SG166117 A1 SG 166117A1 SG 2010071868 A SG2010071868 A SG 2010071868A SG 166117 A1 SG166117 A1 SG 166117A1
Authority
SG
Singapore
Prior art keywords
interferon
treatment
resistant tumors
compositions
methods
Prior art date
Application number
SG201007186-8A
Other languages
English (en)
Inventor
William F Benedict
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Publication of SG166117A1 publication Critical patent/SG166117A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dispersion Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG201007186-8A 2003-12-10 2004-12-10 Methods and compositions for treatment of interferon-resistant tumors SG166117A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52852503P 2003-12-10 2003-12-10

Publications (1)

Publication Number Publication Date
SG166117A1 true SG166117A1 (en) 2010-11-29

Family

ID=34699875

Family Applications (2)

Application Number Title Priority Date Filing Date
SG200704175-9A SG133594A1 (en) 2003-12-10 2004-12-10 Methods and compositions for treatment of interferon-resistant tumors
SG201007186-8A SG166117A1 (en) 2003-12-10 2004-12-10 Methods and compositions for treatment of interferon-resistant tumors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG200704175-9A SG133594A1 (en) 2003-12-10 2004-12-10 Methods and compositions for treatment of interferon-resistant tumors

Country Status (17)

Country Link
US (7) US7691822B2 (fr)
EP (2) EP1691844B1 (fr)
JP (2) JP4801594B2 (fr)
KR (1) KR101163248B1 (fr)
CN (1) CN1893981B (fr)
AT (1) ATE502654T1 (fr)
AU (1) AU2004298991A1 (fr)
BR (1) BRPI0417451A (fr)
CA (1) CA2548100C (fr)
DE (1) DE602004031973D1 (fr)
ES (1) ES2363912T3 (fr)
HK (1) HK1095525A1 (fr)
IL (1) IL175820A0 (fr)
NO (1) NO20062385L (fr)
SG (2) SG133594A1 (fr)
WO (1) WO2005058368A1 (fr)
ZA (1) ZA200604640B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7002027B1 (en) * 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
CA2470999C (fr) * 2001-12-20 2017-02-21 Schering-Plough Corporation Compositions de syn3 et procedes associes
NZ543970A (en) * 2003-06-04 2008-09-26 Canji Inc Methods and compositions for interferon therapy
SG133594A1 (en) * 2003-12-10 2007-07-30 Canji Inc Methods and compositions for treatment of interferon-resistant tumors
WO2006065827A2 (fr) 2004-12-13 2006-06-22 Canji, Inc. Lignees cellulaires pour la production d'adenovirus defectifs pour la replication
US20070249043A1 (en) * 2005-12-12 2007-10-25 Mayall Timothy P Adenoviral expression vectors
EP2001502A1 (fr) * 2006-03-31 2008-12-17 Schering Corporation Dose faible parentérale d'interférons de type 1 pour cancer de la vessie
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
RU2530555C2 (ru) 2008-04-17 2014-10-10 ПиДиЭс БАЙОТЕКНОЛОДЖИ КОРПОРЭЙШН Стимуляция иммунного ответа энантиомерами катионных липидов
CN105101991A (zh) 2012-09-21 2015-11-25 Pds生物科技公司 改进的疫苗组合物和使用方法
CA3005251A1 (fr) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipides en tant que vecteurs synthetiques pour ameliorer le traitement et la presentation de l'antigene ex-vivo en therapie cellulaire dendritique
EP3416727A4 (fr) * 2016-02-15 2019-10-09 FKD Therapies Limited, Thérapie améliorée à base d'interféron
US11311487B2 (en) 2016-04-14 2022-04-26 Trizell Ltd. Viral vector stabilization
CN111655238A (zh) * 2017-12-05 2020-09-11 Pds生物科技公司 用于刺激i型干扰素基因的包括阳离子脂质的方法和组合物
CN111363726A (zh) * 2018-12-26 2020-07-03 上海元宋生物技术有限公司 表达干扰素的溶瘤病毒及其应用
US20200222477A1 (en) * 2019-01-10 2020-07-16 Trizell Ltd. Method to Curtail the Progression of Non-Muscle Invasive Bladder Cancer To Muscle-Invasive Cancer
KR20230013021A (ko) 2020-03-19 2023-01-26 트리젤 엘티디. 온도-반응성 바이러스 저장 시스템
CN115666618A (zh) * 2020-03-30 2023-01-31 崔泽尔有限公司 用于治疗癌症的组合物和方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5618711A (en) * 1986-08-22 1997-04-08 Hoffmann-La Roche Inc. Recombinant expression vectors and purification methods for Thermus thermophilus DNA polymerase
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0331635A3 (fr) * 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Préparation pour le traitement du cancer de la vessie
US6207454B1 (en) 1989-10-16 2001-03-27 Amgen Inc. Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
US5120316A (en) 1990-09-28 1992-06-09 Akzo N.V. Urethral catheter and catheterization process
US5602023A (en) 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US6210939B1 (en) 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
US5552309A (en) 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
EP0804076A4 (fr) * 1994-10-19 1998-10-21 Genetic Therapy Inc Therapie genique par administration concurrente et repetee d'adenovirus et d'agents immunodepresseurs
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
WO1997005209A1 (fr) 1995-07-28 1997-02-13 Kohne David E Procede d'accroissement de la chimioluminescence
US20040014709A1 (en) 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
ZA979295B (en) * 1996-10-18 1998-04-20 Canji Inc Methods and compositions for delivery and expression of interferon-Ó nucleic acids.
US6210969B1 (en) * 1999-04-28 2001-04-03 Coulter International Corp. Composition and method for differentiation of basophil and eosinophil subpopulations of leukocytes in blood
US20040002474A1 (en) * 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
CA2470999C (fr) 2001-12-20 2017-02-21 Schering-Plough Corporation Compositions de syn3 et procedes associes
WO2003073998A2 (fr) * 2002-03-02 2003-09-12 Board Of Regents, The University Of Texas System Production et/ou administration locale d'agents anticancereux par des precurseurs de cellules stromales
NZ543970A (en) * 2003-06-04 2008-09-26 Canji Inc Methods and compositions for interferon therapy
BRPI0410915A (pt) 2003-06-04 2006-06-27 Canji Inc composição farmacêutica, método para fornecer um interferon a um sujeito mamìfero, e, kit
SG133594A1 (en) 2003-12-10 2007-07-30 Canji Inc Methods and compositions for treatment of interferon-resistant tumors
US20070249043A1 (en) 2005-12-12 2007-10-25 Mayall Timothy P Adenoviral expression vectors

Also Published As

Publication number Publication date
US9439977B2 (en) 2016-09-13
BRPI0417451A (pt) 2007-04-10
IL175820A0 (en) 2006-10-05
WO2005058368A1 (fr) 2005-06-30
US20050287119A1 (en) 2005-12-29
ES2363912T3 (es) 2011-08-19
SG133594A1 (en) 2007-07-30
JP4801594B2 (ja) 2011-10-26
NO20062385L (no) 2006-09-05
ATE502654T1 (de) 2011-04-15
CA2548100A1 (fr) 2005-06-30
EP1691844A1 (fr) 2006-08-23
US20200164091A1 (en) 2020-05-28
ZA200604640B (en) 2007-04-25
AU2004298991A1 (en) 2005-06-30
HK1095525A1 (en) 2007-05-11
US7691822B2 (en) 2010-04-06
US20240000968A1 (en) 2024-01-04
EP2301584A1 (fr) 2011-03-30
EP1691844A4 (fr) 2007-11-28
US20190374654A1 (en) 2019-12-12
KR20060127397A (ko) 2006-12-12
JP2011148834A (ja) 2011-08-04
US20210322572A1 (en) 2021-10-21
EP1691844B1 (fr) 2011-03-23
CA2548100C (fr) 2015-03-24
US20160045618A1 (en) 2016-02-18
DE602004031973D1 (de) 2011-05-05
US20100266547A1 (en) 2010-10-21
KR101163248B1 (ko) 2012-07-05
CN1893981A (zh) 2007-01-10
JP2007513963A (ja) 2007-05-31
CN1893981B (zh) 2011-03-23

Similar Documents

Publication Publication Date Title
IL175820A0 (en) Methods and compositions for treatment of interferon-resistant tumors
HK1080517A1 (en) Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
IL175885A0 (en) Monovalent antibody fragments useful as therapeutics
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
IL226717A (en) Isolated nucleic acids encoded by anti-beta human antibodies 7
ES2564463T3 (es) Péptidos antigénicos de Neisseriales
MXPA03000103A (es) Antigenos de streptococcus.
SG165339A1 (en) Incorporation of non-naturally encoded amino acids into proteins
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
SG149000A1 (en) Gag binding proteins
ATE334998T1 (de) Verfahren zur herstellung cyclischer peptide
DE60234085D1 (de) Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor
AU8497701A (en) Claudin polypeptides
ATE402956T1 (de) Neue, mhc klasse ii assoziierte peptide
MXPA05011830A (es) Peptidos para uso en el tratamiento de la obesidad.
WO2002070001A3 (fr) Utilisation de lp82 pour traiter les troubles hematopoietiques
ATE312921T1 (de) Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper
MXPA05011716A (es) Gen, polipeptidos y metodos de uso en ghrh canino.
EP1634954A4 (fr) Protease, adn codant pour cette protease et procede de production de cette protease
DK1578772T3 (da) Cytokiner og cytokinreceptorer med reduceret immunogenicitet
MXPA06013176A (es) Dominios semejantes al factor de crecimiento epidermico de mucina 3.
IL162133A0 (en) Method of increasing protein expression, proteins and polynucleotides
ATE319837T1 (de) Verfahren zur herstellung von rekombinantem trypsin
EP1639109A4 (fr) Vecteurs adn
EP1566386A4 (fr) Gene associe a la calvitie et polypeptide code par ce gene, et utilisations correspondantes